5 days ago
1
TBE/iStock Editorial via Getty Images
Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach the main goal in a Phase 3 trial for adults with giant cell arteritis ((GCA), a vascular disorder.
Citing initial data from its Phase 3 GCAptAIN
© FBT Company 2025. All rights are reserved
English (US) ·